COMPARISON OF THE EFFECTS OF LOSARTAN AND ENALAPRIL ON CLINICAL STATUS AND EXERCISE PERFORMANCE IN PATIENTS WITH MODERATE OR SEVERE CHRONICHEART-FAILURE
K. Dickstein et al., COMPARISON OF THE EFFECTS OF LOSARTAN AND ENALAPRIL ON CLINICAL STATUS AND EXERCISE PERFORMANCE IN PATIENTS WITH MODERATE OR SEVERE CHRONICHEART-FAILURE, Journal of the American College of Cardiology, 26(2), 1995, pp. 438-445
Objectives. This study assessed the feasibility of an efficacy trial c
omparing angiotensin-converting enzyme inhibition and angiotensin II r
eceptor antagonism in heart failure. Patients with moderate or severe
heart failure whose condition had previously been stabilized by treatm
ent with a converting enzyme inhibitor were randomly assigned to recei
ve enalapril or losartan. The study was designed to detect any signs o
f clinical deterioration during double blind treatment. Background. Lo
sartan is a specific, nonpeptide angiotensin II receptor-1 antagonist
with a vasodilator hemodynamic profile similar to that of converting e
nzyme inhibitors. Although therapy with specific receptor blockade has
certain theoretic advantages over nonspecific converting enzyme inhib
ition, demonstration of a comparable therapeutic effect in patients wi
th congestive heart failure will require a major effort comparing two
active agents. Methods. One hundred sixty-six patients with stable hea
rt failure in New York Heart Association functional class III or IV an
d an ejection fraction less than or equal to 35% were included in a mu
lticenter, double blind, parallel, enalapril-controlled trial. After a
3-week stabilization period with optimal therapy, including digitalis
, diuretic drugs and a converting enzyme inhibitor, patients were rand
omly assigned to 8 weeks of therapy with losartan, 25 mg/day (n = 52);
losartan, 50 mg/day (n = 56); or enalapril, 20 mg/day (n = 58). Patie
nts were assessed with frequent clinical and laboratory evaluation and
exercise testing. Results. No significant differences between groups
in terms of changes in exercise capacity (6-min, walk test), clinical
status (dyspnea-fatigue index), neurohumoral activation (norepinephrin
e, N-terminal atrial natriuretic factor), laboratory evaluation or inc
idence of adverse experience were observed. Conclusions. The results s
uggest that losartan and enalapril are of comparable efficacy and tole
rability in the short-term treatment of moderate or severe congestive
heart failure. A trial designed to compare the efficacy, tolerability
and effect on mortality of long-term angiotensin II receptor blockade
with converting enzyme inhibition is both feasible and ethically respo
nsible.